Pregnancy outcome after cabergoline treatment in early weeks of gestation

Reproductive Toxicology

Volumn 16, Issue 6, 2002, Pages 791-793

  Ricci, Elena ^a   Parazzini, Fabio ^a,b   Motta, Tiziano ^b   Ferrari, Carlo I ^c   Colao, Annamaria ^d   Clavenna, Antonio ^a   Rocchi, Francesca ^a   Gangi, Emanuela ^e   Paracchi, Sandra ^f   Gasperi, Maurizio ^g   Lavezzari, Maurizio ^h   Nicolosi, Anna Elisa ^b   Ferrero, Simona ^c   Landi, Maria Luisa ^d   Beck Peccoz, Paolo ^e   Bonati, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Medici di Medicina Generale   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h Direzione Medica   (Italy)

Author keywords

Cabergoline; Drug adverse effects; Newborn; Pregnancy

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ADULT; ARTICLE; CONGENITAL MALFORMATION; DRUG INDUCED DISEASE; ECHOGRAPHY; FEMALE; FEMALE INFERTILITY; GESTATIONAL AGE; GYNECOLOGY; HUMAN; HYDATIDIFORM MOLE; HYPERPROLACTINEMIA; INDUCED ABORTION; ITALY; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PROSPECTIVE STUDY; RISK FACTOR; SPONTANEOUS ABORTION; TERATOGENICITY; TRISOMY 18;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADULT; DOPAMINE AGONISTS; ERGOLINES; FEMALE; GESTATIONAL AGE; HUMANS; ITALY; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 18644377455     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(02)00055-2     Document Type: Article

References (10)

1. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New Engl J Med 1994;331:942-4.
2. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-22.
3. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982;247:1589-91.
4. Beltrame D, Longo M. Mazue G. Reproductive toxicity of cabergoline in mice, rats, and rabbits. Reprod Toxicol 1996;10:471-83.
5. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10(4):333-7.
6. Servizio Osservatorio Epidemiologico 1996. Interruzioni Volontarie di Gravidanza e Aborti Spontanei in Lombardia, Regione Lombardia, Novembre 1997.
7. Rozzi C, Benassi L, Parazzini F, Chatenoud L, La Vecchia C, Benzi G. Trends of spontaneous abortion in Italy, 1990-1995. Epidemiology 2000;11:229-30 [letter].
8. Mazzanti P, La Vecchia C, Parazzini F, Bolis G. Frequency of hydatidiform mole in Lombardy, Northern Italy. Gynecol Oncol 1986;24:337-42.
9. http://www.lshtm.ac.uk/php/eeu/eurocat/A03.html, May 13, 2002.
10. Parazzini F, Pirotta N, La Vecchia C, Fedele L. I determinanti della mortalita' perinatale ed infantile nelle regioni: 1980-1983. Ann Ostet Ginecol Med Perinat 1990;111:9-146.